...
首页> 外文期刊>Cancer gene therapy >Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo
【24h】

Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo

机译:脂质体载体介导的3p FUS1基因的递送在体内证明对人肺癌有效的抗肿瘤活性

获取原文
           

摘要

Lung cancer is one of the leading causes of death in the world. The underlying cause for lung cancer has been attributed to various factors that include alteration and mutation in the tumor suppressor genes. Restoration of normal function of the tumor suppressor gene is a potential therapeutic strategy. Recent studies have identified a group of candidate tumor suppressor genes on human chromosome 3p21.3 that are frequently deleted in human lung and breast cancers. Among the various genes identified in the 3p21.3 region, we tested the antitumor activity of the FUS1 gene in two human non-small-cell lung cancer (NSCLC) xenografts in vivo. Intratumoral administration of FUS1 gene complexed to DOTAP:cholesterol (DOTAP:Chol) liposome into subcutaneous H1299 and A549 lung tumor xenograft resulted in significant (P=.02) inhibition of tumor growth. Furthermore, intravenous injections of DOTAP:Chol–FUS1 complex into mice bearing experimental A549 lung metastasis demonstrated significant (P=.001) decrease in the number of metastatic tumor nodules. Finally, lung tumor-bearing animals when treated with DOTAP:Chol–FUS1 complex demonstrate prolonged survival (median survival time: 80 days, P=.01) compared to control animals. This result demonstrates the potent tumor suppressive activity of the FUS1 gene and is a promising therapeutic agent for treatment of primary and disseminated human lung cancer.
机译:肺癌是世界上主要的死亡原因之一。肺癌的根本原因已归因于各种因素,包括肿瘤抑制基因的改变和突变。恢复肿瘤抑制基因的正常功能是一种潜在的治疗策略。最近的研究已经确定了人类染色体3p21.3上的一组候选肿瘤抑制基因,这些基因在人类肺癌和乳腺癌中经常被删除。在3p21.3区域中鉴定出的各种基因中,我们测试了FUS1基因在体内两种人类非小细胞肺癌(NSCLC)异种移植物中的抗肿瘤活性。将与DOTAP:胆固醇(DOTAP:Chol)脂质体复合的FUS1基因瘤内给药至皮下H1299和A549肺肿瘤异种移植物中,可显着(P = .02)抑制肿瘤生长。此外,向患有实验性A549肺转移的小鼠静脉内注射DOTAP:Chol–FUS1复合物证明转移肿瘤结节数量显着减少(P = .001)。最后,与对照动物相比,用DOTAP:Chol–FUS1复合物治疗的荷瘤动物表现出延长的生存期(中位生存时间:80天,P = .01)。该结果证明了FUS1基因的有效的肿瘤抑制活性,并且是用于治疗原发性和弥散性人肺癌的有前途的治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号